These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27623252)

  • 41. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.
    Carlson JW; Miron A; Jarboe EA; Parast MM; Hirsch MS; Lee Y; Muto MG; Kindelberger D; Crum CP
    J Clin Oncol; 2008 Sep; 26(25):4160-5. PubMed ID: 18757330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers.
    Fakkert IE; Mourits MJ; Jansen L; van der Kolk DM; Meijer K; Oosterwijk JC; van der Vegt B; Greuter MJ; de Bock GH
    Cancer Prev Res (Phila); 2012 Nov; 5(11):1291-7. PubMed ID: 23009828
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
    Sherman ME; Piedmonte M; Mai PL; Ioffe OB; Ronnett BM; Van Le L; Ivanov I; Bell MC; Blank SV; DiSilvestro P; Hamilton CA; Tewari KS; Wakeley K; Kauff ND; Yamada SD; Rodriguez G; Skates SJ; Alberts DS; Walker JL; Minasian L; Lu K; Greene MH
    J Clin Oncol; 2014 Oct; 32(29):3275-83. PubMed ID: 25199754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
    Havrilesky LJ; Moss HA; Chino J; Myers ER; Kauff ND
    Gynecol Oncol; 2017 Jun; 145(3):549-554. PubMed ID: 28390820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
    Schwartz ZP; Li AJ; Walsh CS; Rimel BJ; Alvarado MM; Lentz SE; Cass I
    Gynecol Oncol; 2023 Jun; 173():1-7. PubMed ID: 37030072
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
    Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.
    Marchetti C; De Felice F; Palaia I; Perniola G; Musella A; Musio D; Muzii L; Tombolini V; Panici PB
    BMC Womens Health; 2014 Dec; 14():150. PubMed ID: 25494812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
    Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
    Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
    Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
    Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
    Stroot IAS; Bart J; Hollema H; Jalving M; Wagner MM; Yigit R; van Doorn HC; de Hullu JA; Gaarenstroom KN; van Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez García EB; Ausems MGEM; Boere IA; van Hest LP; Duijkers FAM; van Asperen CJ; Schmidt MK; Wevers MR; Ruijs MWG; Devilee P; Collée JM; Hebon Investigators ; de Bock GH; Mourits MJE
    Gynecol Oncol; 2024 Aug; 187():198-203. PubMed ID: 38795508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
    Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H
    Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
    Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
    BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study.
    Pla-Juher H; Pardo M; Izquierdo ÀJ; Darder E; Carbó A; Munté E; Torres-Esquius S; Balmaña J; Lázaro C; Brunet JM; Barretina-Ginesta MP
    Clin Transl Oncol; 2024 Apr; 26(4):1033-1037. PubMed ID: 37682500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.
    Holman LL; Friedman S; Daniels MS; Sun CC; Lu KH
    Gynecol Oncol; 2014 May; 133(2):283-6. PubMed ID: 24582866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy.
    Poon C; Hyde S; Grant P; Newman M; Ireland Jenkin K
    Int J Gynecol Cancer; 2016 Oct; 26(8):1415-20. PubMed ID: 27488216
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
    Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
    BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
    Wu S; Weinstein SP; DeLeo MJ; Conant EF; Chen J; Domchek SM; Kontos D
    Breast Cancer Res; 2015 May; 17():67. PubMed ID: 25986460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serous tubal intraepithelial carcinoma arising from the intrauterine portion of the fallopian tube after bilateral salpingo-oophorectomy.
    Yoshida H; Shintani D; Imai Y; Fujiwara K
    Eur J Gynaecol Oncol; 2016; 37(3):404-6. PubMed ID: 27352575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
    Mannis GN; Fehniger JE; Creasman JS; Jacoby VL; Beattie MS
    JAMA Intern Med; 2013 Jan; 173(2):96-103. PubMed ID: 23247828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.